Logo image of OXFD

Oxford Immunotec (OXFD) Stock Price, Quote, News and Overview

NASDAQ:OXFD - Nasdaq -

21.99  +0.01 (+0.05%)

After market: 21.99 0 (0%)

OXFD Quote, Performance and Key Statistics

Oxford Immunotec

NASDAQ:OXFD (3/5/2021, 8:00:02 PM)

After market: 21.99 0 (0%)

21.99

+0.01 (+0.05%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High23.11
52 Week Low8.37
Market Cap570.90M
Shares25.96M
Float5.85M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A N/A


OXFD short term performance overview.The bars show the price performance of OXFD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

OXFD long term performance overview.The bars show the price performance of OXFD in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of OXFD is 21.99 null. In the past month the price increased by 0.23%. In the past year, price increased by 69.55%.

Oxford Immunotec / OXFD Daily stock chart

About OXFD

Company Profile

Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom.

Company Info

Oxford Immunotec

94C INNOVATION DRIVE MILTON PARK

ABINGDON X0 OX14 4RZ

CEO: Peter Wrighton-Smith Ph.D.

Phone: 44-0-12-3544-2780

Oxford Immunotec / OXFD FAQ

What is the stock price of Oxford Immunotec today?

The current stock price of OXFD is 21.99 null. The price increased by 0.05% in the last trading session.


What is the ticker symbol for Oxford Immunotec stock?

The exchange symbol of Oxford Immunotec is OXFD and it is listed on the Nasdaq exchange.


On which exchange is OXFD stock listed?

OXFD stock is listed on the Nasdaq exchange.


What is Oxford Immunotec worth?

Oxford Immunotec (OXFD) has a market capitalization of 570.90M null. This makes OXFD a Small Cap stock.


What are the support and resistance levels for Oxford Immunotec (OXFD) stock?

Oxford Immunotec (OXFD) has a support level at 21.95 and a resistance level at 22.29. Check the full technical report for a detailed analysis of OXFD support and resistance levels.


Should I buy Oxford Immunotec (OXFD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Oxford Immunotec (OXFD) stock pay dividends?

OXFD does not pay a dividend.


What is the Price/Earnings (PE) ratio of Oxford Immunotec (OXFD)?

Oxford Immunotec (OXFD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).


OXFD Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to OXFD. When comparing the yearly performance of all stocks, OXFD is one of the better performing stocks in the market, outperforming 71.7% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OXFD Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to OXFD. OXFD has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OXFD Financial Highlights

Over the last trailing twelve months OXFD reported a non-GAAP Earnings per Share(EPS) of -0.2612. The EPS decreased by -120.9% compared to the year before.


Industry RankSector Rank
PM (TTM) -30.51%
ROA -8.3%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-104.75%
Sales Q2Q%-8.4%
EPS 1Y (TTM)-120.9%
Revenue 1Y (TTM)-19.26%

OXFD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 73% to OXFD. The Buy consensus is the average rating of analysts ratings from 3 analysts.


Ownership
Inst Owners88.31%
Ins Owners16.14%
Short Float %N/A
Short RatioN/A
Analysts
Analysts73.4
Price TargetN/A
EPS Next Y-2900%
Revenue Next YearN/A